MGMT, NUPR1, NDRG2, and GLI1 Gene Promoter Methylation in Glioblastoma Tissues and Association with Clinical Characteristics and Therapeutic Outcomes.

Mariam M Gabr, Sherihan G AbdelHamid, Lobna R Ezz El Arab, Menha Swellam, Nadia M Hamdy

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mariam M GabrAin Shams University Hospitals, Abassia, Cairo 11566, Egypt.

Sherihan G AbdelHamidBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt.ORCID 0000-0003-4900-3715

Lobna R Ezz El ArabClinical Oncology Department, Faculty of Medicine, Ain Shams University, Abassia, Cairo 11566, Egypt.

Menha SwellamBiochemistry Department, Biotechnology Research Institute, High Throughput Molecular and Genetic Laboratory, Central Laboratories Network and the Center for Excellences for Advanced Sciences, National Research Centre, Dokki, Giza 12622, Egypt.ORCID 0000-0002-7104-7194

Nadia M HamdyBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt.ORCID 0000-0003-2105-107X

Funding

STDF 25562STDF 4940

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most prevalent and devastating form of primary brain tumors in adults, with dismal survival despite advancements in treatment modalities. The current study sought to develop clinically significant prognostic models for GBM patients by comprehensively profiling MGMT, NUPR1, NDRG2, and GLI1 gene promoter methylation in GBM tissues vs. non-neurooncological disease (NND) and their association with clinical characteristics and therapeutic outcome. This was further evaluated by in silico functional enrichment analysis. NUPR1, NDRG2, and GLI1 gene promoter methylation were significant epigenetic discriminators between GBM and NND. However, NDRG2 methylation was the sole independent predictor for neoplastic lesions (OR = 1.71, 95% CI [1.25-3.57],

Indexed as

Basic Helix-Loop-Helix ProteinsBrain NeoplasmsDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGlioblastomaPromoter Regions, GeneticTumor Suppressor ProteinsZinc Finger Protein GLI1AdultAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedBasic Helix-Loop-Helix ProteinsDNA Modification MethylasesDNA Repair EnzymesGLI1 protein, humanMGMT protein, humanNDRG2 protein, humanNeoplasm ProteinsNUPR1 protein, humanTumor Suppressor ProteinsZinc Finger Protein GLI1bioinformaticsDNA methylationEpigeneticsGLI1glioblastoma (GBM)in silicoMGMTNDRG2NUPR1

Identifiers

PMID41596413

DOI10.3390/ijms27020763

PMCPMC12841541

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.